Selected article for: "international license and vaccine development"

Author: Chi Heem Wong; Kien Wei Siah; Andrew W Lo
Title: Estimating Probabilities of Success of Clinical Trials for Vaccines and Other Anti-Infective Therapeutics
  • Document date: 2020_4_14
  • ID: fnrm6a79_21
    Snippet: In contrast, non-industry-sponsored vaccine development programs have an overall PoS of only 6.8% (SE: 1.0%), with PoS12, PoS23, and PoS3A estimates of 63.3% (SE: 1.8%), 37.3% (SE: 2.6%), and 39.8% (SE: 4.9%), respectively ( Figure 3b ). The top three indications with the highest overall success rates for non-industry-sponsored drug development programs are otitis media (28.6%, SE: 17.1%), rabies (25.0%, SE: 10.8%), and Japanese encephalitis CC-B.....
    Document: In contrast, non-industry-sponsored vaccine development programs have an overall PoS of only 6.8% (SE: 1.0%), with PoS12, PoS23, and PoS3A estimates of 63.3% (SE: 1.8%), 37.3% (SE: 2.6%), and 39.8% (SE: 4.9%), respectively ( Figure 3b ). The top three indications with the highest overall success rates for non-industry-sponsored drug development programs are otitis media (28.6%, SE: 17.1%), rabies (25.0%, SE: 10.8%), and Japanese encephalitis CC-BY 4.0 International license It is made available under a author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

    Search related documents:
    Co phrase search for related documents
    • drug development and japanese encephalitis: 1, 2, 3, 4
    • drug development and non industry: 1, 2, 3, 4, 5, 6, 7, 8
    • drug development and overall pos: 1, 2, 3, 4, 5
    • drug development and SE overall pos: 1, 2
    • drug development and success rate: 1, 2, 3, 4, 5, 6, 7
    • drug development and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • drug development and vaccine development program: 1, 2, 3
    • drug development program and japanese encephalitis: 1
    • drug development program and non industry: 1, 2
    • drug development program and overall pos: 1, 2
    • drug development program and vaccine development: 1, 2, 3, 4
    • drug development program and vaccine development program: 1, 2
    • international license and non industry: 1, 2, 3, 4
    • international license and overall pos: 1, 2, 3
    • international license and SE overall pos: 1, 2, 3
    • international license and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
    • japanese encephalitis and non industry: 1
    • japanese encephalitis and overall pos: 1
    • japanese encephalitis and vaccine development: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16